Belite Bio
BLTE
6 hedge funds and large institutions have $14.9M invested in Belite Bio in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 3 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0.6% more ownership
Funds ownership: 3.53% → 4.12% (+0.6%)
25% less funds holding
Funds holding: 8 → 6 (-2)
41% less capital invested
Capital invested by funds: $25.4M → $14.9M (-$10.5M)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$4.79M |
| 2 |
AWS
Atria Wealth Solutions
New York
|
+$54.5K |
| 3 |
State Street
Boston,
Massachusetts
|
+$20.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.09K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AA
ALPS Advisors
Denver,
Colorado
|
-$458K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$219K |
| 3 |
Morgan Stanley
New York
|
-$13.6K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$3K |
| 5 |
BlackRock
New York
|
-$2.07K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AWS
1
Atria Wealth Solutions
New York
| $11.6M | +$54.5K | +2,400 | +0.3% |
|
|
AC
2
Armistice Capital
New York
| $3.01M | +$4.79M | +210,915 | New |
|
|
3
State Street
Boston,
Massachusetts
| $189K | +$20.9K | +921 | +7% |
|
|
4
BlackRock
New York
| $13.8K | -$2.07K | -91 | -9% |
|
|
5
Morgan Stanley
New York
| $6.26K | -$13.6K | -600 | -58% |
|
|
6
UBS Group
Zurich,
Switzerland
| $4.29K | +$4.09K | +180 | +150% |
|
|
AA
7
ALPS Advisors
Denver,
Colorado
| – | -$458K | -15,786 | Closed |
|
|
8
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$219K | -7,528 | Closed |
|
|
9
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$3K | -94 | Closed |
|
BLTE Hedge Fund Activity: Q2 2023 in Review
6 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Belite Bio (BLTE) for Q2 2023, worth a combined $14.9M — down 41% from $25.4M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of BLTE and 1 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $4.79M. The largest seller was ALPS Advisors, exiting entirely with an estimated $458K sold.
- 6 institutional investors held Belite Bio (BLTE) as of Q2 2023, down from 8 in Q1 2023.
- Funds reported $14.9M of Belite Bio stock for Q2 2023, down 41% quarter-over-quarter.
- 1 fund opened new Belite Bio positions in Q2 2023 and 3 closed out, a net change of -2 holders.
- The largest Belite Bio buyer in Q2 2023 was Armistice Capital, an estimated $4.79M added.
- The largest Belite Bio seller in Q2 2023 was ALPS Advisors, an estimated $458K sold.
Based on aggregated 13F filings for Q2 2023.